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The short chain fatty acid (SCFA) propionate, produced through fermentation of dietary fibre by
the gut microbiota, has been shown to alter hepatic metabolic processes that reduce lipid stor-
age. We aimed to investigate the impact of raising colonic propionate production on hepatic
steatosis in adults with non-alcoholic fatty liver disease (NAFLD). Eighteen adults were random-
ized to receive 20 g/d of an inulin-propionate ester (IPE), designed to deliver propionate to the
colon, or an inulin control for 42 days in a parallel design. The change in intrahepatocellular lipid
(IHCL) following the supplementation period was not different between the groups (P = 0.082),
however, IHCL significantly increased within the inulin-control group (20.9%  2.9% to
26.8%  3.9%; P = 0.012; n = 9), which was not observed within the IPE group (22.6%  6.9%
to 23.5%  6.8%; P = 0.635; n = 9). The predominant SCFA from colonic fermentation of inulin
is acetate, which, in a background of NAFLD and a hepatic metabolic profile that promotes fat
accretion, may provide surplus lipogenic substrate to the liver. The increased colonic delivery of
propionate from IPE appears to attenuate this acetate-mediated increase in IHCL.
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1 | INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), a condition characterized
by the accumulation of fat within the liver, is regarded as a major risk
factor in the development of type 2 diabetes.1 The prevalence of
NAFLD is strongly associated with obesity,1 thus current guidelines
for the prevention and management of NAFLD are based solely on
body weight loss through diet and exercise.1 While lifestyle
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modifications are successful in reducing body weight in the short
term, numerous studies show that long-term maintenance of body
weight loss in obese individuals is very poor.2 Lifestyle modifications
alone are therefore unlikely to reduce the growing prevalence of
NAFLD and there is an urgent need to develop therapeutic interven-
tions that can safely be applied at the population level.
Recent investigations suggest that diet, the gut microbiota and
liver fat storage could be linked through a mechanism involving short
chain fatty acids (SCFA), the major products of dietary fibre fermenta-
tion in the colon. It has been repeatedly observed that when animals
are fed fermentable fibre they are protected against steatosis induced
by high fat diets.3–5 This effect may be because of the SCFA propio-
nate, as ~90% of propionate produced in the colon is extracted from
the portal vein by the liver,6 which has been shown to alter hepatic
metabolic processes to reduce lipid content.7,8 To augment colonic
propionate production we have developed an inulin-propionate ester
(IPE), whereby the SCFA propionate is bound to the dietary fibre inu-
lin, which is released through microbial hydrolysis in the colon.9 Our
recent first-in-human studies provided preliminary evidence that sup-
plementing the diet with 10 g/d IPE for 24 weeks reduced liver fat
content in adults with NAFLD.9 These volunteers were identified as
having NAFLD on the basis of an elevated intrahepatocellular lipid
(IHCL) content from magnetic resonance imaging.
The aim of the current study was to develop in vivo proof-of-
concept for IPE as a therapeutic to reduce hepatic steatosis in volun-
teers with a histological confirmation of NAFLD, which is considered
the gold standard to establish diagnosis. We hypothesized that the addi-
tion of 20 g IPE to the diet of adults with NAFLD for 42 days would
significantly reduce IHCL compared with 20 g of an inulin control.
2 | METHODS
All volunteers provided informed, written consent prior to the clinical
trial which was approved by the London Brent Research Ethics Com-
mittee (14/LO/0645). The study was carried out in accordance with
the Declaration of Helsinki and is registered with the ISRCTN registry
(ISRCTN71814178). A detailed methodology is presented in File S1
for this article. Men and women aged 18 to 65 years, with a body
mass index (BMI) of 20 to 40 kg/m2 were recruited from liver clinics
at St Mary's Hospital, Imperial College Healthcare National Health
Service Trust. Potential volunteers were eligible if they had a confir-
mation of NAFLD by liver biopsy within the previous 5 years and con-
trolled blood glucose levels (HbA1c < 48 mmol/mol). The study was
conducted using a randomized, double-blind, placebo-controlled, par-
allel design. Subjects received either 20 g/d of inulin control or IPE for
42 days. The 20 g dose of IPE would have provided 14.6 g of inulin
(and 5.4 g bound propionate) to the diet.9 Inulin was therefore chosen
as a positive control to account for any effects that may derive from
fermentation of this substrate by the gut microbiota. The supplements
were provided to volunteers in 10 g ready-to-use sachets and they
were instructed to mix the contents into their habitual diet twice a
day. Participants were required to attend the NIHR Imperial Clinical
Research Facility pre- (day 0) and postsupplementation (day 42) to
determine outcome measures.
3 | RESULTS AND DISCUSSION
Of 20 volunteers that were randomized and enrolled into the study,
data were analysed from the 18 volunteers that completed the sup-
plementation period (Figure S1, File S1). The characteristics of these
volunteers are presented in Tables 1 and S1 (File S1). Estimated com-
pliance was similar in the supplementation groups (inulin control:
90%  7% vs. IPE: 95%  2%; P = 0.213). The changes in IHCL
(Figure 1A-C and Table 1) were unexpected, as we observed an
increase in IHCL postsupplementation in both groups (main effect for
time; P = 0.020). The change in IHCL was not significantly different
between supplementation groups (Figure 1A; P = 0.082), however,
within-group analysis showed that IHCL was significantly increased
within the inulin-control group (Figure 1B; P = 0.012) and not the IPE
group (Figure 1C; P = 0.635). Analysis of metabolic and inflammatory
responses (Figure 1D-I, Figure S2; Tables S2-S4, File S1) highlights
that the change in insulin resistance (HOMA-IR) was significantly dif-
ferent between groups (Figure 1D; P = 0.046), with a non-significant
increase in the inulin-control group (Figure 1E; P = 0.060) and
decrease in the IPE group (Figure 1E; P = 0.389), respectively. There
were no within- or between-group differences in body composition
(Table 1), self-reported food intake or physical activity following the
supplementation period (Table S5, File S1). Our hypothesis was that
IPE supplementation would decrease IHCL in adults with NAFLD, as
observed in our previous study9; however, IPE supplementation did
not reduce liver fat content. The disparate outcome may be explained
by methodological differences in IPE dose (10 g/d vs. 20 g/d) and
exposure (6 weeks vs. 24 weeks) in the two studies. Furthermore, vol-
unteers in the current study had a confirmation of NAFLD by liver
biopsy, which is considered the gold standard to establish diagnosis,
and metabolic parameters would indicate these individuals had poorer
glycaemic control compared with the volunteers from our previous
study (fasting glucose: 5.0 mmol/L vs. 6.1 mmol/L; HbA1c: 38 mmol/
mol vs. 42 mmol/mol).
Whilst breath hydrogen, a marker of colonic fermentation, was
elevated in both groups postsupplementation (Table S3, File S1), the
impact on SCFAs measured in peripheral blood was limited, as we
observed that IPE supplementation only reduced levels of butyrate in
fasting samples compared to the inulin-control group (Table S3,
File S1). The blood samples were collected >12 hours after volunteers
were requested to ingest their final supplement, which may explain
why we were unable to detect large differences in circulating SCFAs
postsupplementation. Nevertheless, previous research using stable
isotope methodology has showed that inulin is predominantly fermen-
ted in the human colon into acetate (82%), with considerably less pro-
pionate and butyrate produced (6% and 12%, respectively).10 Dietary
supplementation with inulin-type fructans (ITF) has generally been
associated with positive effects on metabolic health. The evidence for
this beneficial effect is primarily derived from rodent studies, where
dietary supplementation with ITF has consistently been shown to pre-
vent the accumulation of liver fat and metabolic dysregulation induced
by a high fat diet.3–5 However, to the best of our knowledge, ITF have
not been shown to reduce liver fat when added to the diets of rodents
with pre-existing steatosis. Studies investigating the effect of ITF on
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metabolic health in humans are equivocal, with a recent meta-analysis
reporting no association between ITF supplementation and fasting
glucose and insulin levels.11 Fewer studies have quantified the impact
of ITF supplementation on liver fat content in humans. Our previous
work showed that 30 g/d ITF supplemented into the habitual diet of
overweight adults with normal glycaemic control had no effect on
IHCL.12 In contrast, a superior reduction in IHCL in adults with predia-
betes was found when a weight-loss diet was combined with 30 g/d
ITF supplementation.13 The serendipitous observation in the current
study is that supplementing 20 g/d inulin into a habitual weight-
maintaining diet raises IHCL and further exacerbates glucose homeo-
stasis in adults with NAFLD. Taken together, our data suggest that ITF
supplementation does not have a homogenous impact on hepatic lipid
content in humans, and its effects may depend on the pre-existing
metabolic health of the individual and the energy-balance promoted
by the background diet.
Previous research would suggest that the acetate derived from
inulin fermentation would have contrasting metabolic fates depending
on hepatic lipid metabolism in different physiological conditions. For
example, it has previously been reported that greater amounts of
exogenous acetate are used for hepatic de novo lipogenesis (DNL) in
obese compared to lean individuals. This metabolic response was
associated with higher insulin levels in the obese group, which is the
chief regulator of hepatic DNL.14 Previous work has also showed that
chronic intragastric acetate infusion in rats promotes postprandial
hyperinsulinaemia and increases liver triglyceride content.15 The con-
version of SCFAs into metabolic intermediates is initially determined
by the acyl-CoA synthetase short-chain family members (ACSS).16
Human hepatocytes express the cytosolic isoform ACSS2, which has
high specificity for acetate and increases the availability of acetyl-CoA
for lipid synthesis.16 Evidence highlights that, together with higher
insulin levels,17 humans with NAFLD have an elevated expression of
hepatic genes that favour fat accumulation, with increased expression
of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN),
which are key enzymes in hepatic DNL.18 Consequently, NAFLD
patients are reported to have rates of DNL up to 3-fold higher com-
pared with BMI-matched controls.17 The current data suggest that in
body weight-stable individuals with NAFLD, an increased supply of
acetate to the liver from the colonic fermentation of inulin provides
surplus acetyl-CoA for DNL and hepatic lipid accretion. Interestingly,
diet-induced body weight loss in mice has been shown to markedly
reduce insulin levels and rates of hepatic DNL,19 whilst the expression
of hepatic DNL-related genes is also reduced by states of chronic
negative energy balance.20 This may explain the disparate effect of
inulin supplementation on liver fat content in the current study
compared with our previous investigation when inulin intervention
was added to a hypocaloric diet that achieved a ~5% reduction in
body weight.13
IPE supplementation did not significantly raise IHCL content, as
observed within the inulin-control group. The contrasting outcome
could be because of differences in the amounts of acetate derived
from inulin fermentation throughout the supplementation period, as
the inulin-control group were provided with a greater amount of inulin
compared to IPE (20 g/d vs. 14.6 g/d). In vitro faecal fermentation
profiles have previously showed, however, that comparable quantities
of acetate are produced from equivalent doses of inulin and IPE.9
Interestingly, IPE does substantially alter the proportion of SCFAs pro-
duced, as the molar ratio of acetate, propionate and butyrate changes
TABLE 1 Baseline characteristics of volunteers and changes in intrahepatocellular lipid and body composition following 42 days of inulin control
or inulin-propionate ester (IPE) supplementation
Inulin control IPE Mixed ANOVA
(n = 9) (n = 9) Time Group × Time
Variable Pre Post P value Pre Post P value P value P value
Sex (n)
Male 5 4
Female 4 5
Race or ethnicity (n)
White 5 7
Asian 4 2
Age (years) 49  4 51  4
Diabetes (Y/N) 3/6 2/7
Dyslipidaemia (Y/N) 5/4 5/4
Hypertension (Y/N) 2/7 2/7
Liver biopsy histology (NAFLD/NASH) 6/3 7/2
IHCL (%) 20.9  2.9 26.8  3.9 0.012 22.6  6.9 23.5  6.8 0.635 0.020 0.082
Body weight (kg) 83.3  4.4 83.2  4.0 0.914 93.6  7.6 93.9  7.4 0.556 0.438 0.578
BMI (kg/m2) 29.5  1.4 29.5  1.4 0.966 31.5  1.9 31.6  1.9 0.377 0.696 0.620
Fat mass (kg) 26.8  3.4 27.1  3.3 0.524 35.3  5.2 34.9  5.3 0.485 0.931 0.302
Fat free mass (kg) 56.5  3.7 56.1  3.3 0.631 58.3  5.0 59.1  5.2 0.055+ 0.748 0.341
Abbreviations: BMI, body mass index; IHCL, intrahepatocellular lipid; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
+ = non-parametric statistical analysis.
Detailed volunteer characteristics are presented in Table S1, File S1.
Data are expressed as mean  SEM.
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from 74:16:10 with inulin to 25:69:6 with an equivalent amount of
IPE.9 It could be suggested that the elevated ratio of colonic propio-
nate : acetate promoted by IPE supplementation may have prevented
the accumulation of liver fat observed in the inulin-control group by
impairing hepatic acetate metabolism. This proposed mechanism is
concordant with the results from Wolever and colleagues, who
showed using stable isotope technology that propionate inhibits
incorporation of colonic [1,2-13C] acetate into plasma lipids in
humans.7 Studies using rat hepatocytes have also highlighted that pro-
pionate inhibits lipid synthesis when acetate is a major source of
acetyl-CoA.8 Recent evidence has showed a third ACSS isoform,
ACSS3, for which propionate is the preferred substrate over acetate,
and which is highly expressed in the mitochondrial matrix of hepato-
cytes.16 ACSS3 converts propionate to propionyl-CoA allowing it to
enter mitochondrial respiration through succinate and the TCA
cycle.16 Elevating hepatic propionate metabolism would therefore
increase competition with acetate for conversion into their CoA
adducts at tissue level, which may reduce cytosolic acetyl-CoA avail-
ability for DNL. This potential mechanism is supported by a recent
observation that exposing HepG2 cells to elevated ratios of propio-
nate : acetate increases the formation of heptadecanoic acid derived
from propionyl-CoA, which inhibits the synthesis of palmitate from
acetyl-CoA.21
The present study has a number of potential limitations, chiefly,
the considerable variability in metabolic health of the recruited volun-
teers. Nevertheless, the individual change in IHCL postsupplementa-
tion was not associated with any baseline metabolic variable
(Table S6, File S1) and significant differences between groups at base-
line were only found in two outcome measures (cholesterol and LDL-
cholesterol). In addition, the inclusion criteria permitted a histological
diagnosis of NAFLD within the previous 5 years, thus a volunteer's
histological characterization could have changed in the timeframe
between initial diagnosis and recruitment into the study. However, all
volunteers exhibited a raised IHCL (>5%) when assessed at baseline
(Table S1, File S1).
In conclusion, inulin consumed at 20 g/d increased IHCL in body
weight-stable adults with NAFLD, an effect not observed with IPE
supplementation. We speculate that in the context of NAFLD and a
hepatic metabolic profile that stimulates DNL, the acetate derived
from colonic fermentation of inulin could provide an additional lipo-
genic precursor to the liver. The increased colonic delivery of propio-
nate from IPE appears to attenuate this acetate-mediated increase in
FIGURE 1 Effects of 42 days of inulin control and inulin-propionate ester (IPE) supplementation on liver fat and glucose homeostasis. A to C,
Intrahepatocellular lipid (IHCL); D to F, homeostatic model assessment of insulin resistance (HOMA-IR); and G to I, glycosylated haemoglobin
(HbA1c). Group data (A, D and G) are expressed as mean  SEM (n = 9)
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IHCL, possibly by interfering with the availability of acetate-derived
acetyl-CoA for DNL. Further work is warranted to explore how altering
colonic SCFA production profiles modulates the metabolic pathways
that govern hepatic lipid storage in humans. In particular, future research
should determine how the hepatic metabolic processing of acetate and
propionate changes in different states of energy balance, and how to
make distinctions between NAFLD patients and healthy controls.
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